Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes

Return to Grants

Grant Award Details

Grant Type:
Quest – Discovery Stage Research Projects
Grant Number:
DISC2-12124
Investigator(s):
Name:
Dr Eiji Yoshihara PhD
Institution:
Lundquist Institute for Biomedical Innovation at Harbor – UCLA Medical Center
Type:
PI

Disease Focus:
Diabetes, Metabolic Disorders, Type 1 diabetes
Human Stem Cell Use:
Embryonic Stem Cell
Award Value:
$250,000
Status:
Closed

Progress Reports

Reporting Period:
Year 1

Grant Application Details

Application Title:

Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes

Public Abstract:
Research Objective

Functional human islet like organoids differentiated from human pluripotent stem cells.

Impact

Providing the immediate cell therapeutic candidate for clinical trial of diabetic patients.

Major Proposed Activities

  • Fabrication and characterization of the injectable immunomodulating and pro-angiogenic material components: HA hydrogel, heparin nanoparticles and VEGF clusters.
  • Generation of human islet like organoids from pluripotent stem cells for subcutaneous transplantation
  • Subcutaneous HILOs transplantation in pre-vasculature site in NOD-SCID mice.
  • Subcutaneous PD-L1 expressing HILOs transplantation in pre-vasculature site in Hu-PBMC-NSG mice
Statement of Benefit to California:
The cell and technology products proposed by this diabetes therapeutic study will significantly improve future diabetes treatments in the State of California, particularly benefiting vulnerable populations, such as Hispanics, African-Americans, men, older populations, homeless individuals, and those of lower socioeconomic status. Additionally, this proposed research may create greater research employment opportunities in the South Bay, a region within Los Angeles County.

Publications